CeloNova BioSciences Reports Yokohama Hospital Research Shows New Class Of Stent Effective In Preventing Thrombosis, Restenosis, And Reocclusion
10/2/2008 9:02:37 AM
Medical News Today -- CeloNova BioSciences, Inc., announced that Masahiko Ochiai MD, Associate Professor, Division of Cardiology, Yokohama Hospital, Kanagawa, Japan has selected the CATANIA(TM) Coronary Stent System featuring NanoThin Polyzene(R)-F for treating a patient with a chronic total occlusion (CTO) during a live case symposium at the Paris Cardiovascular Interventions (Francophone) Congress. The CATANIA(TM) Coronary Stent System carries a CE Mark and is currently available for sale in Europe.
comments powered by